*.- En Pacientes con Avanzado LPS o LMS, Yondelis Redujo Significativamente el riesgo de progresión de la enfermedad o la muerte en un 45% en comparación con quienes recibieron Dacarbacina (cociente de riesgo [CR] = 0.550; P < 0.0001; mediana [M] 4.2 vs 1.5 meses, respectivamente), con resultados validados a través de una auditoría por radiólogos independientes. *.- El Beneficio PFS fue Mejorado Constantemente con el Tratamiento Yondelis en todos los subgrupos clínicamente relevantes y fue apoyado por una tasa de respuesta objetiva aumento (ORR), una mayor duración de la respuesta (DOR) y una mayor tasa de respuesta de beneficio clínico en comparación con Dacarbazina.
*.- En el análisis intermedio para la supervivencia total (OS), la prueba aún no había encontrado el punto final primario de OS.
*.- El estudio aún esta en curso para determinar los resultados Finales de Supervivencia Total ( OS ) , que serán presentados en una futura reunión.
*.- Los resultados para los puntos finales de eficacia secundarios son maduros.
**********************************************************************************
Yondelis Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma . SOURCE Janssen Research & Development, LLC .
CHICAGO and RARITAN, N.J., June 1, 2015 /PRNewswire/ --
Oral Presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.
Janssen Research & Development, LLC (Janssen) announced data from the Phase 3 multicenter study SAR3007, which demonstrated a significant improvement in progression-free survival (PFS) with trabectedin (YONDELIS®) compared to dacarbazine in patients with advanced liposarcoma (LPS) or leiomyosarcoma (LMS) previously treated with an anthracycline and at least one additional chemotherapy regimen. SAR3007 is the largest randomized Phase 3 study ever conducted in this patient population. These data were presented today in an oral presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL.
Soft tissue sarcoma (STS) is a type of cancer originating in the soft tissues that connect, support and surround other body structures, such as muscle, fat, blood vessels, nerves, tendons and the lining of joints.[1],[2] LPS and LMS are among the most common types of STS in adults and represent approximately 40-50% of all STS cases.[3],[4]
"Advanced soft tissue sarcomas represent a complex set of rare diseases which, when advanced, are life threatening. Our patients need new treatment options that are effective and reasonably well tolerated, as the treatment landscape has been relatively stagnant for decades," said George Demetri, M.D., Director, Center for Sarcoma and Bone Oncology at the Dana-Farber Cancer Institute and Professor at Harvard Medical School. "In soft tissue sarcomas, disease stabilization is an important metric for evaluating treatment success in patients with advanced disease. The safety data from this trial were consistent with the well-defined adverse events observed in previous clinical trials of trabectedin and in clinical use outside the United States where trabectedin has been approved to treat these aggressive diseases."
Trabectedin is approved in 77 countries in North America, Europe, South America and Asia under the trade name YONDELIS® for the treatment of advanced STS as a single agent. Janssen submitted a New Drug Application for YONDELIS® to the U.S. Food and Drug Administration on November 24, 2014, which was granted Priority Review on February 3, 2015.
"The data presented at ASCO underscore the value of trabectedin as a potentially important treatment option for patients with LPS and LMS subtypes of soft tissue sarcoma," said Craig Tendler, M.D., Vice President, Late Development and Global Medical Affairs, Oncology, Janssen. "This latest research underlines our long-standing commitment to patients with advanced soft tissue sarcoma. To date, more than 50,000 patients worldwide have been treated with YONDELIS®, including approximately 3,000 patients in our Expanded Access Program in the United States."
I n this randomized, active-controlled Phase 3 study in patients with advanced LPS or LMS, trabectedin significantly reduced the risk of disease progression or death by 45% compared with those who received dacarbazine (hazard ratio [HR] = 0.550; P< 0.0001; median [M] 4.2 vs. 1.5 months, respectively), with results validated through an audit by independent radiologists. The improved PFS benefit with trabectedin treatment was consistently observed across all clinically relevant subgroups and was further supported by an increased objective response rate (ORR), a longer duration of response (DOR), and a higher clinical benefit response rate as compared to dacarbazine. At the interim analysis for overall survival (OS), the trial had not met the primary endpoint of OS. The study is ongoing to determine the final OS results, which will be presented at a future meeting. The results for the secondary efficacy endpoints are mature. Safety findings were consistent with the well-characterized safety profiles of both agents, with the most common Grade 3-4 toxicities in the trabectedin versus the dacarbazine groups being decreased absolute neutrophil count (40% vs. 25%), decreased platelets (19% vs. 20%), and transient increases in liver transaminases, including alanine transaminase (ALT) (29% vs. 1%). Drug-related deaths occurred in 2.1% of patients in the trabectedin group versus 0% of patients in the dacarbazine group.